維亞生物(01873.HK)擬25.6億元收購朗華製藥80%股權
格隆匯 8 月 9日丨維亞生物(01873.HK)發佈公告，2020年8月8日，公司間接全資附屬公司維亞生物科技(上海)作為買方訂立股份購買協議，據此，維亞生物科技(上海)同意收購及賣方同意共同出售朗華製藥80%的股權，代價為人民幣25.60億元(相當於約28.42億港元)，將以現金支付。
根據披露，朗華製藥集團為一間位於浙江省台州的綜合及全面藥品研發及製造公司。其獲評為2017年醫藥國際化百強企業榜單中最具成長力企業之一。朗華製藥集團於醫藥行業享負盛名。其已獲得國家藥品監督管理局(NMPA)的GMP認證，並獲得美國食品藥品監督管理局(FDA)、歐洲藥物質量管理局(EDQM)及世界衞生組織(WHO)以及醫藥供應鏈管理委員會(PSCI)的官方認證。其致力成為其客户(包括全球多間跨國醫藥公司)優選的合同開發及製造組織(CDMO)夥伴。
賣方為朗華製藥的六名現有股東。於該公告日期，中寧化集團、諾柏投資、致寧投資、單孟春、楊諾及班豔分別持有朗華製藥股權的約55.01%、22.00%、7.50%、6.00%、4.99%及4.50%。各賣方現時有意將其持有的80%股權出售予維亞生物科技(上海)。
朗華製藥為一間於中國成立的有限公司。其主要從事小分子原料藥和中間體生產和CDMO業務。於該公告日期，朗華製藥由賣方所有。諾柏醫藥為一間於中國成立的有限公司，主要從事醫藥產品商業化相關服務，且為朗華製藥的直接全資附屬公司。諾柏醫藥與朗華製藥共同為醫藥合作伙伴提供涵蓋醫藥產品開發至商業化的一站式解決方案。諾柏香港為一間於香港成立的有限公司，為與諾柏醫藥的海外客户進行離岸訂約的實體。諾柏香港為諾柏醫藥的直接全資附屬公司。完成後，朗華製藥將成為公司的非全資附屬公司，並將作為經擴大集團小分子藥及中間體的唯一CDMO平台。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
